Xellia pays steep price for factory delays
Novo company Xellia Pharmaceuticals has not generated the profits which it had hoped for and instead presents a notable deficit for 2020. The firm blames competitive prices and factory issues.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Following last year's record profit, Xellia Pharmaceuticals seemed to have started a new growth spurt, but this did not turn out to be the case. Danish media Børsen reports that instead, the firm reports a DKK 133m (USD 21.8m) deficit for 2020 compared to its DKK 400m profit in 2019.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
